Towards a Risk-Benefit Evaluation of Placebos
Wiener Medizinische Wochenschrift. 1998; 148(20): 461-463.
The notion that placebo can, in certain circumstances, represent a valuable and ethical therapeutic intervention has been repeatedly reconsidered in recent years. This article discusses the possibility of submitting placebos to a conventional risk-benefit evaluation. The benefits of placebos are often not clearly defined. Generally speaking, the potential for benefit is considerable. The risks are similarly ill defined. Both direct and indirect risks are conceivable. On balance, the risk-benefit relation for placebo could be favourable. Under certain conditions, the clinical use of placebos might therefore be a realistic option. In the final analysis, however, our knowledge for a conclusive risk-benefit evaluation of placebo is incomplete.
Showing items related by title, author, creator and subject.
Calculating risk/benefit in X-linked severe combined immune defieciency disorder (X-SCID) gene therapy trials: the task of ethical evaluation Swazo, Norman K. (2006-10)In response to adverse events in retroviral gene therapy clinical trials conducted in France to correct for X-linked severe combined immune deficiency disorder (X-SCID), an advisory committee of the Food and Drug Administration ...